標題: Titlebook: Drug Repurposing; Innovative Approache Naveen Chella,Om Prakash Ranjan,Amit Alexander Book 2024 The Editor(s) (if applicable) and The Autho [打印本頁] 作者: CK828 時間: 2025-3-21 19:29
書目名稱Drug Repurposing影響因子(影響力)
書目名稱Drug Repurposing影響因子(影響力)學科排名
書目名稱Drug Repurposing網(wǎng)絡(luò)公開度
書目名稱Drug Repurposing網(wǎng)絡(luò)公開度學科排名
書目名稱Drug Repurposing被引頻次
書目名稱Drug Repurposing被引頻次學科排名
書目名稱Drug Repurposing年度引用
書目名稱Drug Repurposing年度引用學科排名
書目名稱Drug Repurposing讀者反饋
書目名稱Drug Repurposing讀者反饋學科排名
作者: 精美食品 時間: 2025-3-21 21:59
Vision: Past, Present, and Future,ng the likelihood of a drug being approved. Additionally, it has the potential to expedite the discovery and development of new treatments, which could benefit patients by providing more treatment options and reducing the time and costs associated with bringing new drugs to market. Any medicine, whe作者: corpus-callosum 時間: 2025-3-22 04:24 作者: Meander 時間: 2025-3-22 06:09 作者: LAITY 時間: 2025-3-22 11:53
to the implementation of nanotechnology, photo-thermal therapy, immunotherapy, and gene therapy. However, most available standard and novel therapies face economic challenges, and some suffer from regulatory burdens. New clonal aberrations, multidrug resistance, cyclic occurrence of mutation, and h作者: 有特色 時間: 2025-3-22 13:13 作者: 有特色 時間: 2025-3-22 17:50 作者: overwrought 時間: 2025-3-22 23:08
https://doi.org/10.1007/978-88-470-2244-7eases include alkaptonuria, Ehlers-Danlos syndrome, neurofibromatosis, and hereditary angioedema. Patients with rare diseases frequently experience significant challenges getting a prompt and correct diagnosis, getting appropriate treatments, and acquiring support from the healthcare system due to t作者: SCORE 時間: 2025-3-23 02:57
https://doi.org/10.1007/978-3-642-81306-1s for emerging diseases in the current era. Drug repurposing has become more popular as an effective technique to discover novel treatment strategies for a plethora of disorders, intending to reduce both the time and expense involved with the process of drug development. Drug repurposing is the appr作者: Choreography 時間: 2025-3-23 06:16 作者: 提名 時間: 2025-3-23 12:09 作者: innovation 時間: 2025-3-23 14:05 作者: NATTY 時間: 2025-3-23 21:39
978-981-97-5018-4The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor作者: 淺灘 時間: 2025-3-23 23:53 作者: 沙文主義 時間: 2025-3-24 06:17
http://image.papertrans.cn/e/image/284833.jpg作者: 協(xié)定 時間: 2025-3-24 08:57 作者: GOAD 時間: 2025-3-24 11:38
Methodologies Adopted in Drug Repurposing,ng the likelihood of a drug being approved. Additionally, it has the potential to expedite the discovery and development of new treatments, which could benefit patients by providing more treatment options and reducing the time and costs associated with bringing new drugs to market. Any medicine, whe作者: 手勢 時間: 2025-3-24 18:31
In Silico Methods Used in Drug Repurposing, of research funding. This strategy is particularly intriguing in many pharmaceutical targets, given the significant expense of finding novel medications with therapeutic promise. Computational approaches have been used to predict relationships between drugs and their targets. Numerous computational作者: gimmick 時間: 2025-3-24 21:25
Role of Artificial Intelligence (AI) and Machine Learning (ML) in Drug Purposing,ve time and avoid substantial financial loss to the pharmaceutical industry. Utilizing the already authorized drugs for novel indications (drug repositioning) has shortened wait times and boosted success rates. To date, various approaches have been used for the repurposing of the drugs. However, the作者: 使絕緣 時間: 2025-3-25 01:58 作者: Ancestor 時間: 2025-3-25 05:20
Drug Repurposing in Inflammatory Disorders,me other medical conditions. It is essential because it may significantly save the time, expense, and risk involved in creating new medications from scratch while offering new therapeutic alternatives to patients with unmet medical requirements. Drug repurposing offers several compelling advantages 作者: 輪流 時間: 2025-3-25 10:08 作者: condescend 時間: 2025-3-25 14:54
Reshaping the Therapeutic Landscape: Drug Repurposing for Emerging Infectious Diseases and Rare Diseases include alkaptonuria, Ehlers-Danlos syndrome, neurofibromatosis, and hereditary angioedema. Patients with rare diseases frequently experience significant challenges getting a prompt and correct diagnosis, getting appropriate treatments, and acquiring support from the healthcare system due to t作者: 繼而發(fā)生 時間: 2025-3-25 17:18 作者: MAL 時間: 2025-3-25 20:31 作者: abolish 時間: 2025-3-26 00:53 作者: Commemorate 時間: 2025-3-26 06:04 作者: inflame 時間: 2025-3-26 12:29
have shown positive results. Even some anticancer agents confirmed their potential effects in other cancers. Here, data mining approaches have been found rationale to provide strength in the repurposing pipeline. Especially if dose compatibility of the repurposed candidate is found for anticancer t作者: Catheter 時間: 2025-3-26 15:58
ge or infection and is involved in the pathophysiology of almost all diseases. But inflammation can turn into the dark side of the sword when it affects healthy tissues or extends to the body as a whole for a long time, referred to as chronic inflammation. Even though there are various treatments fo作者: 雀斑 時間: 2025-3-26 17:01
https://doi.org/10.1007/978-94-011-9839-4 computational approaches. In addition, a few case studies involving drug repurposing for specific CNS disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis, Spinal muscular atrophy, and Epilepsy are presented in this chapter.作者: Humble 時間: 2025-3-26 23:39 作者: 助記 時間: 2025-3-27 01:21
https://doi.org/10.1007/978-3-642-81306-1cessful and old examples of drug repurposing mentioned in literature include sildenafil, aspirin, and zidovudine. The approval by the Food and Drug Administration (FDA) for the use of several repurposed drugs for COVID-19 treatment on an emergency basis has brought attention to the practice of drug 作者: 剝皮 時間: 2025-3-27 06:51
Diane R. Dowd,Paul N. MacDonaldhapter covers drug regulatory and intellectual property rights (IPR) related aspects of drug repurposing. The goal is to help practitioners understand regulatory issues for drugs or product modifications and the repositioning of existing substances. The regulatory background and examples of drug mod作者: invulnerable 時間: 2025-3-27 11:30 作者: Host142 時間: 2025-3-27 13:39
Methodologies Adopted in Drug Repurposing, anecdotes, and other relevant human data is a crucial step. In this process, Artificial Intelligence (AI), bioinformatics, genetic data, clinical analysis, molecular docking, pathways, signatures, targets, phenotypes, and binding tests can help understand drug–protein interactions. The current chap作者: 詢問 時間: 2025-3-27 21:20
Drug Repurposing in Cancer Therapy, have shown positive results. Even some anticancer agents confirmed their potential effects in other cancers. Here, data mining approaches have been found rationale to provide strength in the repurposing pipeline. Especially if dose compatibility of the repurposed candidate is found for anticancer t作者: 缺陷 時間: 2025-3-28 00:19
Drug Repurposing in Inflammatory Disorders,ge or infection and is involved in the pathophysiology of almost all diseases. But inflammation can turn into the dark side of the sword when it affects healthy tissues or extends to the body as a whole for a long time, referred to as chronic inflammation. Even though there are various treatments fo作者: 滲入 時間: 2025-3-28 03:49
Drug Repurposing in CNS Disorders, computational approaches. In addition, a few case studies involving drug repurposing for specific CNS disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis, Spinal muscular atrophy, and Epilepsy are presented in this chapter.作者: frenzy 時間: 2025-3-28 08:14 作者: 不可磨滅 時間: 2025-3-28 11:42
Clinical Trials on Repurposed Drugs: An Overview,cessful and old examples of drug repurposing mentioned in literature include sildenafil, aspirin, and zidovudine. The approval by the Food and Drug Administration (FDA) for the use of several repurposed drugs for COVID-19 treatment on an emergency basis has brought attention to the practice of drug 作者: Endemic 時間: 2025-3-28 17:23
Intellectual Property Rights and Regulatory Considerations Throughout Drug Repurposing,hapter covers drug regulatory and intellectual property rights (IPR) related aspects of drug repurposing. The goal is to help practitioners understand regulatory issues for drugs or product modifications and the repositioning of existing substances. The regulatory background and examples of drug mod作者: 儀式 時間: 2025-3-28 19:35
Redirection to the Drug Discovery: Antidiabetic Drugs Repurposing in Cancer,recently approved drugs are repurposed drugs. However, a few challenges need to be addressed before proceeding with the repurposing. The present chapter coveres different approaches, strategies, and challenges of drug repurposing. The chapter lists the number of clinical trials conducted or complete作者: STENT 時間: 2025-3-29 02:39 作者: 火花 時間: 2025-3-29 07:02
